Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy. - Masri A; Cappelli F; Davis MK; Fontana M; Garcia-Pavia P; Gillmore JD; Hanna M; Obici L; Solomon SD; Sperry BW; Tahara N; Waddington-Cruz M; et al. (Circulation. Heart failure, 2026)